Published in Hepatology on April 01, 2009
Hepatitis C Virus(HCV) Heart and Lung Study | NCT02858180
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6) | NCT01949168
Prospective Comparison Between TE, SWE and MRE (FULLFIBRO01) (FULLFIBRO01) | NCT03293953
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect (2013) 2.09
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol (2013) 1.89
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut (2013) 1.88
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology (2010) 1.84
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.60
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One (2014) 1.58
Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther (2011) 1.57
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J (2013) 1.52
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (2015) 1.48
Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. Dig Dis Sci (2011) 1.47
Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors. Hepat Mon (2012) 1.45
Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One (2012) 1.43
An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis (2013) 1.42
Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. Dig Dis Sci (2010) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41
Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterol Hepatol (N Y) (2013) 1.40
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39
Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection. Dig Dis Sci (2014) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat (2011) 1.37
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (2011) 1.32
Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat (2010) 1.31
Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol (2012) 1.30
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol (2011) 1.29
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Racial differences in hepatitis C treatment eligibility. Hepatology (2011) 1.28
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J (2013) 1.27
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep (2013) 1.27
IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One (2012) 1.25
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2014) 1.23
MicroRNAs and liver disease. Transl Res (2011) 1.21
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A (2011) 1.19
New perspectives in occult hepatitis C virus infection. World J Gastroenterol (2012) 1.17
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit. RNA (2010) 1.17
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med (2011) 1.17
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med (2013) 1.16
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int (2011) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis (2013) 1.15
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Barriers to hepatitis C treatment. Liver Int (2012) 1.13
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis (2012) 1.10
Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn (2011) 1.10
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther (2013) 1.09
Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One (2012) 1.09
Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? J Gastroenterol (2013) 1.08
Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J (2010) 1.08
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology (2014) 1.08
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver (2012) 1.08
Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol (2010) 1.07
Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol (2012) 1.06
Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol (2014) 1.05
Words matter: Discussing research towards an HIV cure in research and clinical contexts. J Acquir Immune Defic Syndr (2014) 1.04
High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis (2011) 1.04
Hepatitis C virus in pregnancy. Am J Perinatol (2013) 1.03
Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc (2011) 1.03
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther (2013) 1.03
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Liver biopsy. Hepatology (2009) 7.61
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Diagnosis and management of autoimmune hepatitis. Hepatology (2010) 5.27
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
AASLD guidelines for treatment of chronic hepatitis B. Hepatology (2015) 3.32
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology (2010) 2.83
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology (2005) 2.28
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl (2005) 2.06
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol (2014) 1.84
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Diagnosis and management of hemochromatosis. Hepatology (2001) 1.81
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. Gastroenterology (2009) 1.67
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
Prospective study of infective endocarditis among injection drug users. J Infect Dis (2002) 1.41
Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology (2006) 1.38
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J (2006) 1.36
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol (2004) 1.34
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
The Gastroenterology Core Curriculum, Third Edition. Gastroenterology (2007) 1.31
Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29
Training the gastroenterologist of the future: the Gastroenterology Core Curriculum. Gastroenterology (2003) 1.29
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis (2008) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend (2004) 1.28
High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis (2013) 1.26